Clinical Trial Update: Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD) [Phase 3]

View source ↗

Summary

A Phase 3 pediatric trial evaluated the safety and efficacy of paricalcitol capsules in lowering serum parathyroid hormone levels in children aged 10-16 with ch…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Paricalcitol capsules (paricalcitol)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Chronic Kidney Disease Stage 3 and 4 | Phase 3 | Status: COMPLETED | Results posted: 2017-03-29